Cluster Headaches

A POSSIBLE ADDITIONAL INDICATION
FOR INTRANASAL OCTREOTIDE

Cluster Headache (CH)

CH common (300,000 U.S. prevalence) and severe (“red hot metal passing through your skull”) Trigeminal Autonomic Cephalgia (TAC) headache

Octreotide Mechanism of Action (MOA) well suited as alternative treatment option

Mechanism can be effective
Calcitonin Gene-Related Peptide (CGRP) inhibition lowers trigeminal nerve sensitivity & inflammation
Vasoactive Intestinal Polypeptide (VIP) inhibition reduces vasodilation

Mechanism can be safe in cardiovascular risk patients

No vasoconstrictive properties
Triptans, which also lower CGRP and VIP, are vasoconstrictive

In a double-blind, placebo-controlled study of 57 patients using SubQ Octreotide

52%

of Octreotide patients experienced relief within 30 minutes

30%

of Octreotide patients were pain free within 30 minutes

52%

of Octreotide patients
experienced relief within 30 minutes

30%

of Octreotide patients
were pain free within 30 minutes